2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5522 Characteristics and long-term outcomes of patients with chronic-phase chronic myeloid leukemia who received ponatinib for at least 5 years in the phase 2 optic trial

James K. McCloskey, MD, Hagop Kantarjian, MD2, Tammie Yeh, PhD3, Evan Reddick4, Lingli Yang5, Jing Xu6, Alexander Vorog, MD7, Venkatesh Ganapathy, MD8, Jorge Cortes, MD9
1 The John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, New Jersey, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
4 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
5 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
6 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
7 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
8 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
9 O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, Alabama, United States

Introduction: Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), potently inhibits wildtype and mutant BCR::ABL1, including T315I. The phase 2 OPTIC trial (NCT02467270) was designed to prospectively identify the response-based dosing strategy that optimizes the benefit:risk profile of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant or intolerant to ≥2 prior TKIs or with a T315I mutation. The primary analysis demonstrated optimal benefit:risk with a ponatinib 45-mg starting dose reduced to 15 mg upon achieving a response of ≤1% BCR::ABL1IS. Results of the final 5-year follow-up demonstrated durable efficacy and long-term tolerability. Understanding patients with long treatment durations may provide insights into dosing and characteristics associated with long-term efficacy and safety. Here, we describe exploratory post hoc analyses in patients who received ponatinib for ≥5 years in OPTIC.

Methods: Patients were randomized to ponatinib starting doses of 45 mg, 30 mg, or 15 mg once daily, with dose reduction to 15 mg once daily upon achievement of ≤1% BCR::ABL1IS in the 45-mg and 30-mg cohorts. Those who received ponatinib for ≥5 years in OPTIC were termed long-term treated (LTT) patients. Outcomes included baseline characteristics, progression-free survival (PFS), overall survival (OS), molecular response (≤1% BCR::ABL1IS and ≤0.1% BCR::ABL1IS), BCR::ABL1 mutation status, and arterial occlusive events (AOEs). Age at baseline and number of prior TKIs in LTT patients were compared to non-LTT patients with <5 years of ponatinib treatment using a 2-sample t-test and Fisher’s exact test, respectively. PFS and OS were assessed using Kaplan-Meier. Molecular responses were assessed at end of study (EOS). Mutation analyses were conducted with blood samples collected at baseline and EOS. Exposure-adjusted rates of AOEs in OPTIC were calculated per 100 patient-years (PY).

Results: Of 282 patients treated with ponatinib, 85 (30.1%) remained on treatment for ≥5 years in OPTIC and were considered LTT patients, with treatment durations ranging from 60 to 105 months at EOS. At EOS, 65/85 (76.5%) continued ponatinib beyond study completion (ie, through post-trial access), while 20/85 (23.5%) discontinued treatment before EOS due to reasons such as adverse events or progressive disease. LTT patients were significantly younger than non-LTT patients (median, 44 years vs 51 years; P=0.0001) and were numerically more likely to have received fewer prior TKIs (2 prior TKIs, 50.6% vs 40.1%; 3 prior TKIs, 42.4% vs 44.7%; 4 prior TKIs, 7.1% vs 12.2%; P=0.1425). Additionally, LTT patients had better PFS and OS on ponatinib than non-LTT patients. A higher proportion of LTT patients were observed in the 45-mg cohort (42.6%) than in the 30-mg (21.3%) and 15-mg (26.6%) cohorts. Among patients with baseline T315I mutations in the 45-mg cohort, 48.0% were LTT patients compared with 9.1% and 9.5% in the 30-mg and 15-mg cohorts, respectively. Rates of ≤1% BCR::ABL1IS and ≤0.1% BCR::ABL1IS at EOS were 70.6% and 57.6%, respectively, in LTT patients. At baseline, 60.0% of LTT patients had no BCR::ABL1 mutations, 15.3% had single T315I mutations, 3.5% had T315I mutations with another mutation, and 17.6% had single or multiple non-T315I mutations; baseline mutation status was unknown in 3 patients. Of the 15 patients with paired baseline and EOS mutation data, 2 (1 in the 45-mg cohort, 1 in the 15-mg cohort) had new non-T315I mutations identified at EOS, both of whom discontinued treatment due to lack of efficacy and progressive disease, respectively, at 75 months. Exposure-adjusted AOE rates per 100 PYs in LTT patients were 0.82 (95% confidence interval [CI] 0–1.95), 0.83 (95% CI 0–2.45), and 1.30 (95% CI 0–3.09) in the 45-mg, 30-mg, and 15-mg cohorts, respectively.

Conclusion: Nearly one-third of patients in OPTIC remained on ponatinib for ≥5 years regardless of baseline BCR::ABL1 mutation status. This long-term treatment was associated with less prior TKI exposure, younger age, high rates of molecular response, minimal emergent mutations, and low rates of AOEs and occurred more commonly in the 45-mg cohort, especially in patients with T315I mutations. These findings support the use of ponatinib as early as indicated in patients with resistant CP-CML and provide additional evidence for ponatinib 45 mg as the optimal starting dose and a durable treatment option that can maintain responses for ≥5 years.

James K. McCloskey, MD: Blueprint Oncology - Honoraria; Pfizer - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony)